Cyclacel Pharmaceuticals (NASDAQ:CYCC) Issues Quarterly Earnings Results, Misses Expectations By $0.01 EPS

Share on StockTwits

Cyclacel Pharmaceuticals (NASDAQ:CYCC) posted its earnings results on Tuesday. The biotechnology company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.01), Morningstar.com reports.

Shares of NASDAQ CYCC remained flat at $$0.48 during midday trading on Thursday. 62,406 shares of the stock were exchanged, compared to its average volume of 71,286. The stock has a market cap of $8.66 million, a P/E ratio of -0.77 and a beta of 2.98. Cyclacel Pharmaceuticals has a 1 year low of $0.28 and a 1 year high of $1.87. The company has a debt-to-equity ratio of 0.08, a quick ratio of 8.09 and a current ratio of 8.09. The firm’s fifty day moving average is $0.56.

Several equities research analysts recently commented on CYCC shares. Roth Capital reiterated a “buy” rating on shares of Cyclacel Pharmaceuticals in a research report on Thursday, May 23rd. HC Wainwright reiterated a “buy” rating on shares of Cyclacel Pharmaceuticals in a research report on Wednesday, May 15th. Finally, Zacks Investment Research downgraded shares of Cyclacel Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, July 16th. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $5.00.

An institutional investor recently raised its position in Cyclacel Pharmaceuticals stock. Renaissance Technologies LLC raised its position in Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) by 82.5% during the second quarter, according to its most recent filing with the SEC. The firm owned 1,102,400 shares of the biotechnology company’s stock after purchasing an additional 498,200 shares during the period. Renaissance Technologies LLC owned 6.41% of Cyclacel Pharmaceuticals worth $596,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 5.36% of the company’s stock.

Cyclacel Pharmaceuticals Company Profile

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include CYC065, a cyclin dependent kinase Inhibitors (CDK) that is in Phase I clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase I clinical trial for the treatment of advanced leukemias.

Further Reading: Google Finance Portfolio Workaround

Earnings History for Cyclacel Pharmaceuticals (NASDAQ:CYCC)

Receive News & Ratings for Cyclacel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.